Abstract:BackgroundHypoxia-inducible factor 2 alpha (HIF2α), prolyl hydroxylase domain protein 2 (PHD2), and the von Hippel Lindau tumor suppressor protein (pVHL) are three principal proteins in the oxygen-sensing pathway. Under normoxic conditions, a conserved proline in HIF2α is hydroxylated by PHD2 in an oxygen-dependent manner, and then pVHL binds and promotes the degradation of HIF2α. However, the crystal structure of the HIF2α-pVHL complex has not yet been established, and this has limited research on the interaction between HIF and pVHL. Here, we constructed a structural model of a 23-residue HIF2α peptide (528–550)-pVHL-ElonginB-ElonginC complex by using homology modeling and molecular dynamics simulations. We also applied these methods to HIF2α mutants (HYP531PRO, F540L, A530 V, A530T, and G537R) to reveal structural defects that explain how these mutations weaken the interaction with pVHL.MethodsHomology modeling and molecular dynamics simulations were used to construct a three-dimensional (3D) structural model of the HIF2α-VHL complex. Subsequently, MolProbity, an active validation tool, was used to analyze the reliability of the model. Molecular mechanics energies combined with the generalized Born and surface area continuum solvation (MM-GBSA) and solvated interaction energy (SIE) methods were used to calculate the binding free energy between HIF2a and pVHL, and the stability of the simulation system was evaluated by using root mean square deviation (RMSD) analysis. We also determined the secondary structure of the system by using the definition of secondary structure of proteins (DSSP) algorithm. Finally, we investigated the structural significance of specific point mutations known to have clinical implications.ResultsWe established a reliable structural model of the HIF2α-pVHL complex, which is similar to the crystal structure of HIF1α in 1LQB. Furthermore, we compared the structural model of the HIF2α-pVHL complex and the HIF2α (HYP531P, F540L, A530V, A530T, and G537R)-pVHL mutants on the basis of RMSD, DSSP, binding free energy, and hydrogen bonding. The experimental data indicate that the stability of the structural model of the HIF2α-pVHL complex is higher than that of the mutants, consistently with clinical observations.ConclusionsThe structural model of the HIF2α-pVHL complex presented in this study enhances understanding of how HIF2α is captured by pVHL. Moreover, the important contact amino acids that we identified may be useful in the development of drugs to treat HIF2a-related diseases.

Exploring the inhibition mechanism on HIF-2 by inhibitor PT2399 and 0X3 using molecular dynamics simulations.

Molecular Dynamics Investigation of Stereoselective Inhibition Mechanism of HIF‐2α/ARNT Heterodimer

Analysis of the binding mode of a novel HIF1α inhibitor through molecular modelling.

Identification of Inhibitors Targeting HIF-2α/c-Myc by Molecular Docking and MM-GBSA Technology

Homology Modeling and Molecular Dynamics Simulation of the HIF2α Degradation-Related HIF2α-VHL Complex.

Insight into the Binding Mode of HIF-2 Agonists Through Molecular Dynamic Simulations and Biological Validation

Exploring the Selective Mechanism of Inhibitors Towards Different Subtypes of Class I PI3K

Effect of Substituents in Different Positions of Aminothiazole Hinge-Binding Scaffolds on Inhibitor–CDK2 Association Probed by Interaction Entropy Method

Understanding the Selectivity of Inhibitors Toward PI4KIIIα and PI4KIIIβ Based Molecular Modeling

Molecular Modeling and Molecular Dynamics Simulation Studies on Pyrrolopyrimidine-Based Α-Helix Mimetic As Dual Inhibitors of MDM2 and MDMX

An efficient strategy for digging protein-protein interactions for rational drug design - A case study with HIF-1α/VHL

Molecular docking based screening of a simulated HIF-1 protein model for potential inhibitors

QSAR Modeling and in Silico Design of Small-Molecule Inhibitors Targeting the Interaction Between E3 Ligase VHL and HIF-1$$\alpha $$Α

Development of Inhibitors Targeting Hypoxia-Inducible Factor 1 and 2 for Cancer Therapy

Discovery of novel inhibitors disrupting HIF-1 alpha/von Hippel-Lindau interaction through shape-based screening and cascade docking

Molecular mechanism study of several inhibitors binding to BRD9 bromodomain based on molecular simulations

Inhibition Mechanism of Hydroxyproline-Like Small Inhibitors to Disorder HIF-VHL Interaction by Molecular Dynamic Simulations and Binding Free Energy Calculations

Discovery of novel inhibitors disrupting HIF-1α/von Hippel–Lindau interaction through shape-based screening and cascade docking

Cancer Therapeutic Agents Targeting Hypoxia-Inducible Factor-1

Studies on Interactions Between Tie-2/VEGFR2 and Dihydroindazolocarbazole Dual Inhibitors Via Molecular Docking

Exploration of Potential RSK2 Inhibitors by Pharmacophore Modelling, Structure-Based 3D-QSAR, Molecular Docking Study and Molecular Dynamics Simulation